alvocidib + cytarabine

Alvocidib + cytarabine is a combination therapy under investigation primarily for the treatment of acute myeloid leukemia (AML), especially in relapsed/refractory and newly diagnosed patients with poor prognostic factors. Alvocidib is a potent, multi-cyclin-dependent kinase inhibitor, most notably targeting CDK9. By inhibiting CDK9, alvocidib suppresses RNA polymerase II-mediated transcription of anti-apoptotic proteins such as MCL-1, leading to increased apoptosis in leukemia cells and sensitization to other chemotherapeutic agents[1][3][6]. Cytarabine is an antimetabolite that interferes with DNA synthesis by incorporating into DNA during the S-phase of the cell cycle and inhibiting DNA polymerase activity[2][8]. The combination exploits sequential cell cycle arrest (alvocidib) followed by S-phase-specific cytotoxicity (cytarabine), resulting in synergistic anti-leukemic effects. This regimen has shown improved complete response rates compared to standard therapies in clinical trials for AML[3][6].